| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 02/12/2009 | WO2009020058A1 Drug delivery system toward demyelinating lesion and biochemical marker of demyelinating lesion |
| 02/12/2009 | WO2009019504A1 Drug combinations for the treatment of duchenne muscular dystrophy |
| 02/12/2009 | WO2009002652A9 Use of surfactants for treating mycobacterial infections |
| 02/12/2009 | WO2008144061A3 Novel combinations comprising a phosphodiesterase-5 inhibitor and their use |
| 02/12/2009 | WO2008033460A3 Treating pain, diabetes, and lipid metabolism disorders |
| 02/12/2009 | US20090043379 Drug delivery systems for the prevention and treatment of vascular diseases |
| 02/12/2009 | US20090042911 Drug combinations comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-YL](3R,5S)-3, 5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of P450 isoenzyme 3A4 |
| 02/12/2009 | US20090042827 Antiviral oligonucleotides targeting hbv |
| 02/12/2009 | US20090042826 Use of the AXL receptor for diagnosis and treatment of renal disease |
| 02/12/2009 | US20090042807 By reducing macrophage NO production through administration of one or more enzyme inhibitors, selected from tripeptides, tetrapeptides and pentapeptides; inhibition of neucrosis factor kappa Beta mediated inflammatory cytokine release |
| 02/12/2009 | US20090042796 Derivatives of the il-2 receptor gamma chain, their production and use |
| 02/12/2009 | US20090042771 Dietary lipids for improving skin and coat of pets |
| 02/12/2009 | US20090042225 Method for selecting therapeutic agents for cancer treatment |
| 02/12/2009 | US20090042221 Preparing biopsy of tumorous tissue and monitoring chemosensitivity to anticarcinogenic agents; antitumor agents; drug screening |
| 02/12/2009 | US20090042199 Nucleotide sequences coding lymphocyte adhesion protein for use in treatment of autoimmunity, inflammation and infection |
| 02/12/2009 | US20090041840 Positive wakeup pharmaceutical sleep system with compatible pre-bedtime administration |
| 02/12/2009 | US20090041792 Dendritic cells, uses therefor, and vaccines and methods comprising the same |
| 02/12/2009 | US20090041788 Apo-2L receptor agonist and CPT-11 synergism |
| 02/12/2009 | US20090041760 Retroviral immunotherapy |
| 02/12/2009 | US20090041759 Materials and methods for treating ocular-related disorders |
| 02/12/2009 | US20090041745 Modulators of paraptosis and related methods |
| 02/12/2009 | US20090041740 Cancer treatment by metabolic modulations |
| 02/12/2009 | US20090041731 Treatment for Diabetes |
| 02/12/2009 | US20090041717 High affinity human antibodies to human nerve growth factor |
| 02/12/2009 | US20090041697 Film-Forming Compositions for Protecting Skin From Body Fluids and Articles Made Therefrom |
| 02/12/2009 | US20090041675 Organic compounds |
| 02/12/2009 | CA2695734A1 Use of interleukin-22 in the treatment of fatty liver disease |
| 02/12/2009 | CA2695365A1 Method of treating cxcr3 mediated diseases using heterocyclic substituted piperazines |
| 02/12/2009 | CA2686616A1 New treatment for chemical substance addiction |
| 02/12/2009 | CA2685740A1 Drug combinations for the treatment of duchenne muscular dystrophy |
| 02/12/2009 | CA2685540A1 Drug combinations for the treatment of duchenne muscular dystrophy |
| 02/11/2009 | EP2022800A2 Compositions for the therapy and diagnosis of ovarian cancer |
| 02/11/2009 | EP2022498A2 Neuroendocrine tumour treatment |
| 02/11/2009 | EP2022495A1 Composition for preventing the occurrence of cardiovascular event in multiple risk patient |
| 02/11/2009 | EP2021000A2 Neurogenesis by modulating angiotensin |
| 02/11/2009 | EP2020857A2 Antimicrobial therapy for bacterial infections |
| 02/11/2009 | EP1549950B1 Methods for identifying glucose uptake modulators |
| 02/11/2009 | EP1317258B1 Use of allopurinol for the treatment of hypertension |
| 02/11/2009 | EP1309334B1 Combination therapy using reovirus and anti-antireovirus antibodies for the treatment of ras-mediated proliferative disorders |
| 02/11/2009 | EP1210453B1 Hdac4 and hdac5 in the regulation of cardiac gene expression |
| 02/11/2009 | CN101365438A Composition for prevention of recurrence of stroke |
| 02/11/2009 | CN101365433A Iontophoresis preparation |
| 02/11/2009 | CN101365425A Drug delivery system for bioadhesion to a vulvovaginal surface |
| 02/11/2009 | CN101365423A Sustained release small molecule drug formulation |
| 02/11/2009 | CN101361974A Medicine combination for preventing and treating osteoporosis |
| 02/11/2009 | CN101361723A Improved pharmaceutical compositions |
| 02/11/2009 | CN101361704A Double sustained release gel injection |
| 02/11/2009 | CN100460874C Method for sieving crimp-relevant protain activator or antagonist |
| 02/11/2009 | CN100460412C Process for preparing amine platinum complexes |
| 02/10/2009 | US7488829 Diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use |
| 02/10/2009 | US7488803 Anticancer agents; two primordial germ cell-specific expressed genes, Fragilis and Stella; as markers for primordial germ cells |
| 02/10/2009 | US7488754 Method for the treatment of polycystic kidney disease |
| 02/10/2009 | US7488735 antagonists of M3 muscarinic receptors; N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-hydroxy-2,2-dithien-2-ylacetamide; respiratory disorders, urological disorders, gastrointestinal disorders, cardiovascular disorders; alkylation |
| 02/10/2009 | US7488734 Anticancer agents; hormone replacement therapy; contraceptives |
| 02/10/2009 | US7488710 Proteins containing the motif that are capable of binding to secreted Frizzled-related protein (Sfrp) family members |
| 02/10/2009 | US7488498 Controlled release nateglimide formulation; reducing blood glucose concentration |
| 02/10/2009 | US7488497 Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a NSAID |
| 02/10/2009 | US7488496 Antiulcer agents (H2-antagonists such as ranitidine and cimetidine); for treating osteoporosis |
| 02/10/2009 | US7488490 Synergistic mixture of oligonucleotides and antigen; induce immunology response |
| 02/10/2009 | CA2383659C Mesoprogestins (progesterone receptor modulators) as a component of compositions for hormone replacement therapy (hrt) |
| 02/10/2009 | CA2380904C Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer |
| 02/10/2009 | CA2344086C Human monoclonal antibody against a costimulatory signal transduction molecule ailim and pharmaceutical use thereof |
| 02/10/2009 | CA2339299C Method of modulating memory effector t-cells and compositions |
| 02/10/2009 | CA2286671C Method and formulation for treating vascular disease |
| 02/10/2009 | CA2280628C Soft chewable tablets |
| 02/05/2009 | WO2009017838A2 Combinations of jak-2 inhibitors and other agents |
| 02/05/2009 | WO2009017701A2 Anti-mitotic agent and aurora kinase inhibitor combination as anti-cancer treatment |
| 02/05/2009 | WO2009017104A1 Protective agent against damage of biological tissue caused by near-infrared ray, and product comprising the same |
| 02/05/2009 | WO2009017052A1 Osteoarthritis-sensitive gene |
| 02/05/2009 | WO2009016072A2 A morpholinyl anthracycline derivative combined with protein kinase inhibitors |
| 02/05/2009 | WO2009016018A1 Compositions comprising polyphenol |
| 02/05/2009 | WO2009015734A2 Dosage form comprising immediate release naproxen and sustained release opioid analgesic |
| 02/05/2009 | WO2008137787A3 Combination therapy with a compound acting as a platelet adp receptor inhibitor |
| 02/05/2009 | WO2008005686A8 Compositions comprising a dissociated glucocorticoid receptor agonist and an immunosuppressive agent for treating dry eye |
| 02/05/2009 | WO2007103042A3 Mycoplasma hyopneumoniae vaccine |
| 02/05/2009 | US20090036761 Noninvasive measurement of chemical substances |
| 02/05/2009 | US20090036544 Methods and compositions for inhibiting the proliferation of prostate cancer cells |
| 02/05/2009 | US20090036517 Anti-angiogenic compositions and methods of use |
| 02/05/2009 | US20090036495 Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists |
| 02/05/2009 | US20090036487 Combinations |
| 02/05/2009 | US20090036432 Combinations of AT1-antagonists, amiloride or triamterine, and a diuretic |
| 02/05/2009 | US20090036412 Methods and Compositions for Inhibition of Angiogenesis |
| 02/05/2009 | US20090036411 Modulation of cell fates and activities by phthalazinediones |
| 02/05/2009 | US20090036408 Compositions and methods for combination antiviral therapy |
| 02/05/2009 | US20090036392 Composition comprising biodegradable hydrating ceramics for controlled drug delivery |
| 02/05/2009 | US20090036360 Medicament containing activated antithrombin iii |
| 02/05/2009 | US20090036352 Drug delivery systems for the prevention and treatment of vascular diseases comprising rapamycin and derivatives thereof |
| 02/05/2009 | US20090035391 Nasal Irrigation Solutions And Methods Of Using Same |
| 02/05/2009 | US20090035349 Composite scaffolds and methods using same for generating complex tissue grafts |
| 02/05/2009 | US20090035315 Method of Improving Treatments in Rheumatic and Arthritic Diseases |
| 02/05/2009 | US20090035297 Methods for treating diabetes |
| 02/05/2009 | US20090035270 COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNF alpha |
| 02/05/2009 | US20090035266 Immunogenic peptides and methods of use |
| 02/05/2009 | US20090035265 Compositions and Methods for Targeted Delivery of Factors |
| 02/05/2009 | US20090035224 Methods of Using Albuterol and Calcium Activated Potassium Channel Openers |
| 02/05/2009 | CA2700004A1 Novel immunotherapy strategy |
| 02/05/2009 | CA2695307A1 Protective agent against damage of biological tissue caused by near-infrared ray and product comprising the same |
| 02/05/2009 | CA2694378A1 Pharmaceutical compositions and process for making them |
| 02/05/2009 | CA2694218A1 Anti-mitotic agent and aurora kinase inhibitor combination as anti-cancer treatment |
| 02/04/2009 | EP2020239A1 Use of IL-174 agonists for treating infectious diseases |